Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus CHILDREN S ALLEGRA HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus CHILDREN S ALLEGRA HIVES.
BENADRYL PRESERVATIVE FREE vs CHILDREN'S ALLEGRA HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Category C
Category C
Antihistamine
Antihistamine